CD276 and prostate cancer: B7-H3 ADCs are currently being studied in medulloblastoma, peritoneal cancer, neuroblastoma, glioma, prostate cancer, head and neck cancer, non-small cell lung cancer, urothelial cancer, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, and Wilms’ tumour [128].